Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Corrigendum to 'Study of the time course of the clinical effect of propofol compared with the time course of the predicted effect-site concentration: performance of three pharmacokinetic-dynamic models' [Br J Anaesth 2010; 104: 452-458].

Coppens M, Van Limmen JGM, Schnider T, Wyler B, Bonte S, Dewaele F, Struys MMRF, Vereecke HEM.

Br J Anaesth. 2019 Feb;122(2):287. doi: 10.1016/j.bja.2018.11.017. Epub 2018 Dec 14. No abstract available.

PMID:
30686316
2.

Indolizine-Based Scaffolds as Efficient and Versatile Tools: Application to the Synthesis of Biotin-Tagged Antiangiogenic Drugs.

Arvin-Berod M, Desroches-Castan A, Bonte S, Brugière S, Couté Y, Guyon L, Feige JJ, Baussanne I, Demeunynck M.

ACS Omega. 2017 Dec 31;2(12):9221-9230. doi: 10.1021/acsomega.7b01184. Epub 2017 Dec 27.

3.

Machine learning based brain tumour segmentation on limited data using local texture and abnormality.

Bonte S, Goethals I, Van Holen R.

Comput Biol Med. 2018 Jul 1;98:39-47. doi: 10.1016/j.compbiomed.2018.05.005. Epub 2018 May 7.

PMID:
29763764
4.

Nanobody Based Dual Specific CARs.

De Munter S, Ingels J, Goetgeluk G, Bonte S, Pille M, Weening K, Kerre T, Abken H, Vandekerckhove B.

Int J Mol Sci. 2018 Jan 30;19(2). pii: E403. doi: 10.3390/ijms19020403.

5.

The checkpoint for agonist selection precedes conventional selection in human thymus.

Verstichel G, Vermijlen D, Martens L, Goetgeluk G, Brouwer M, Thiault N, Van Caeneghem Y, De Munter S, Weening K, Bonte S, Leclercq G, Taghon T, Kerre T, Saeys Y, Van Dorpe J, Cheroutre H, Vandekerckhove B.

Sci Immunol. 2017 Feb 24;2(8). pii: eaah4232. doi: 10.1126/sciimmunol.aah4232.

6.

Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities.

Van Caeneghem Y, De Munter S, Tieppo P, Goetgeluk G, Weening K, Verstichel G, Bonte S, Taghon T, Leclercq G, Kerre T, Debets R, Vermijlen D, Abken H, Vandekerckhove B.

Oncoimmunology. 2017 Jan 19;6(3):e1283460. doi: 10.1080/2162402X.2017.1283460. eCollection 2017.

7.

Healthy brain ageing assessed with 18F-FDG PET and age-dependent recovery factors after partial volume effect correction.

Bonte S, Vandemaele P, Verleden S, Audenaert K, Deblaere K, Goethals I, Van Holen R.

Eur J Nucl Med Mol Imaging. 2017 May;44(5):838-849. doi: 10.1007/s00259-016-3569-0. Epub 2016 Nov 23. No abstract available.

PMID:
27878594
8.

The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.

Willemen Y, Van den Bergh JM, Bonte SM, Anguille S, Heirman C, Stein BM, Goossens H, Kerre T, Thielemans K, Peeters M, Van Tendeloo VF, Smits EL, Berneman ZN.

Oncotarget. 2016 Nov 8;7(45):73960-73970. doi: 10.18632/oncotarget.12170.

9.

Investigation of the Pyridinium Ylide--Alkyne Cycloaddition as a Fluorogenic Coupling Reaction.

Bonte S, Ghinea IO, Dinica R, Baussanne I, Demeunynck M.

Molecules. 2016 Mar 10;21(3):332. doi: 10.3390/molecules21030332.

10.

Humanized Mice to Study Human T Cell Development.

Bonte S, Snauwaert S, Vanhee S, Dolens AC, Taghon T, Vandekerckhove B, Kerre T.

Methods Mol Biol. 2016;1323:253-72. doi: 10.1007/978-1-4939-2809-5_21.

PMID:
26294414
11.

In vitro generation of mature, naive antigen-specific CD8(+) T cells with a single T-cell receptor by agonist selection.

Snauwaert S, Verstichel G, Bonte S, Goetgeluk G, Vanhee S, Van Caeneghem Y, De Mulder K, Heirman C, Stauss H, Heemskerk MH, Taghon T, Leclercq G, Plum J, Langerak AW, Thielemans K, Kerre T, Vandekerckhove B.

Leukemia. 2014 Apr;28(4):830-41. doi: 10.1038/leu.2013.285. Epub 2013 Oct 4.

PMID:
24091848
12.

Novel one-pot green synthesis of indolizines biocatalysed by Candida antarctica Lipases.

Dinica RM, Furdui B, Ghinea IO, Bahrim G, Bonte S, Demeunynck M.

Mar Drugs. 2013 Feb 6;11(2):431-9. doi: 10.3390/md11020431.

13.

Catalyst-free synthesis of quinazolin-4-ones from (hetero)aryl-guanidines: application to the synthesis of pyrazolo[4,3-f]quinazolin-9-ones, a new family of DYRK1A inhibitors.

Debray J, Bonte S, Lozach O, Meijer L, Demeunynck M.

Mol Divers. 2012 Nov;16(4):659-67. doi: 10.1007/s11030-012-9397-7. Epub 2012 Sep 19.

PMID:
22991074
14.

Study of the time course of the clinical effect of propofol compared with the time course of the predicted effect-site concentration: Performance of three pharmacokinetic-dynamic models.

Coppens M, Van Limmen JG, Schnider T, Wyler B, Bonte S, Dewaele F, Struys MM, Vereecke HE.

Br J Anaesth. 2010 Apr;104(4):452-8. doi: 10.1093/bja/aeq028. Epub 2010 Feb 26. Erratum in: Br J Anaesth. 2019 Feb;122(2):287.

15.

The accuracy and clinical feasibility of a new bayesian-based closed-loop control system for propofol administration using the bispectral index as a controlled variable.

De Smet T, Struys MM, Neckebroek MM, Van den Hauwe K, Bonte S, Mortier EP.

Anesth Analg. 2008 Oct;107(4):1200-10. doi: 10.1213/ane.0b013e31817bd1a6.

PMID:
18806028
16.

Spectral analysis and fingerprinting for biomedia characterisation.

Pons MN, Le Bonté S, Potier O.

J Biotechnol. 2004 Sep 30;113(1-3):211-30. Review.

PMID:
15380657

Supplemental Content

Support Center